Alto Neuroscience (NYSE:ANRO) Hits New 52-Week High – Here’s What Happened

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) reached a new 52-week high on Tuesday . The stock traded as high as $28.85 and last traded at $26.7020, with a volume of 43532 shares trading hands. The stock had previously closed at $28.03.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. HC Wainwright reiterated a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Bank of America started coverage on shares of Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price on the stock. Robert W. Baird decreased their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $35.00 target price on shares of Alto Neuroscience in a report on Monday, March 16th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Price Performance

The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $924.45 million, a P/E ratio of -10.87 and a beta of 1.04. The business has a 50 day simple moving average of $22.92 and a 200-day simple moving average of $20.96.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Analysts predict that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Quantinno Capital Management LP grew its position in Alto Neuroscience by 1.4% in the 1st quarter. Quantinno Capital Management LP now owns 36,069 shares of the company’s stock worth $811,000 after purchasing an additional 490 shares during the last quarter. Torren Management LLC bought a new stake in shares of Alto Neuroscience during the fourth quarter valued at approximately $62,000. XTX Topco Ltd boosted its position in shares of Alto Neuroscience by 32.2% during the fourth quarter. XTX Topco Ltd now owns 20,824 shares of the company’s stock worth $371,000 after buying an additional 5,078 shares during the period. Renaissance Technologies LLC grew its holdings in Alto Neuroscience by 6.3% in the 1st quarter. Renaissance Technologies LLC now owns 103,499 shares of the company’s stock worth $2,327,000 after buying an additional 6,100 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Alto Neuroscience by 26.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 39,324 shares of the company’s stock worth $884,000 after buying an additional 8,148 shares in the last quarter.

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.